Arvinas, Inc. (ARVN) is a New Haven, Connecticut-based clinical-stage biotechnology company and a pioneer in targeted protein degradation through its PROTAC (PROteolysis TArgeting Chimera) platform. Its lead program, VEPPANU (vepdegestrant), was approved by the FDA in May 2026 for ESR1-mutated advanced breast cancer.
A review of nine current, individually attributed sell-side targets — spanning Barclays ($20), Citigroup ($21), Evercore ISI ($14), BofA Securities ($15), H.C. Wainwright ($13), Wedbush ($12), Wells Fargo ($11), Morgan Stanley ($10), and Leerink Partners ($8) — produces an arithmetic mean of about $13.80, rounded to a $14 central target. The range is unusually wide, from $8 to $21, and Goldman Sachs has been among the most cautious with a $6 target. Notably, these targets have been falling: Citigroup trimmed its target from $24 to $21, Wells Fargo downgraded the stock to a hold-equivalent rating, and several firms lowered targets after third-quarter results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Bullish analysts emphasize the validated degrader platform and the value of the Rigel licensing deal, while cautious analysts point to weak commercial prospects and a shrinking near-term pipeline. This spread explains why the average analyst price target sits far above the current price even as ratings have drifted toward "hold."
Arvinas shares closed near $6.80 in mid-November 2026, not far above a 52-week range of roughly $6.41 to $13.83 and down more than 40% over the trailing year. Reaching the $14 central target would require an approximate 106% advance — a very large move that would effectively restore the stock to its early-2026 levels before the post-approval decline.
The company's finances are unusual for a biotech: revenue is milestone-driven and lumpy, with Q2 2026 revenue of $249.7 million (including a $50 million Pfizer milestone) collapsing to $0.5 million in Q3 2026. Arvinas reported a Q3 net loss of roughly $53.9 million but holds more than $550 million in cash, funding operations into the second half of 2028. With a market capitalization near $500 million, the stock trades close to its net cash position, which some investors view as a valuation floor.
Arvinas has been in a persistent downtrend, now trading within a few percent of its 52-week low near $6.41. That level is the nearest meaningful support. On the upside, former support around $8 to $9, the psychologically important $10 level, and the 52-week high near $13.83 all stand between the current price and the $14 target. A sustained move toward the target would require clearing each of these resistance zones, which have coincided with earlier failed rebounds. From what I see, the technical setup remains challenging until those levels are cleared.
Analyst price targets typically reflect a 12-month research horizon, though individual firms vary. Investors focused on this $14 stock price target should watch the ASH 2026 presentation of ARV-393 data, any ARV-102 neurological readouts, VEPPANU launch progress reported by Rigel, quarterly cash burn, and any new partnership or licensing activity. Further analyst revisions — up or down — following these catalysts will likely move the consensus materially, given how wide the current range already is.
I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For investors tracking a volatile name like Arvinas, automated signal generation can help flag momentum changes as clinical and commercial catalysts unfold.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 260 similar instances where the Aroon Indicator formed such a pattern. In 226 of the 260 cases the stock moved lower. This puts the odds of a downward move at 87%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 55 cases where ARVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.592). P/E Ratio (21.367) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapies to degrade disease-causing proteins
Industry Biotechnology